Drugs other than COX inhibitors have been shown to interfere with the NF-κB pathway in various malignancies, e.g., glucocorticoids, while being pro-apoptotic in leukemia and lymphomas, have been found to enhance survival of some breast cancer cell lines through promoting NF-κB transcriptional activity leading to upregulation of c-Myc and enhanced anti-apoptotic function (62, 63). This evidence concerns the gene NFKB1 and breast carcinoma.